ciglitazone has been researched along with Disease Exacerbation in 2 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most thyroid cancers are slow-growing, easily treatable tumors with an excellent prognosis after surgical resection and targeted medical therapy." | 2.43 | Identification and treatment of aggressive thyroid cancers. Part 2: risk assessment and treatment. ( Angelos, P; Sturgeon, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Konturek, PC | 1 |
| Nikiforuk, A | 1 |
| Kania, J | 1 |
| Raithel, M | 1 |
| Hahn, EG | 1 |
| Mühldorfer, S | 1 |
| Sturgeon, C | 1 |
| Angelos, P | 1 |
1 review available for ciglitazone and Disease Exacerbation
| Article | Year |
|---|---|
Identification and treatment of aggressive thyroid cancers. Part 2: risk assessment and treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Cisplat | 2006 |
1 other study available for ciglitazone and Disease Exacerbation
| Article | Year |
|---|---|
Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.
Topics: Aged; Aged, 80 and over; Barrett Esophagus; Blotting, Western; Cyclooxygenase Inhibitors; Disease Pr | 2004 |